1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Mulhern, T.D. Shaw, G.L. Morton, C.J. Day, A.J. Campbell, I.D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C9 H12 N O6 P 261.168 n O-PHOSPHOTYROSINE PHOSPHONOTYROSINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Structure STRUE6 2005 0969-2126 5 1313 1323 10.1016/S0969-2126(97)00283-9 9351806 The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity. 1997 GW Eur.Biophys.J. EBJOE8 0997 0175-7571 24 371 Solution Studies of the Sh2 Domain from the Fyn Tyrosine Kinase: Secondary Structure, Backbone Dynamics and Protein Association 1996 10.2210/pdb1aot/pdb pdb_00001aot 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 12299.815 FYN PROTEIN-TYROSINE KINASE 2.7.1.112 SH2 DOMAIN C97S, C98S, C104S 1 man polymer 1473.515 PHOSPHOTYROSYL PEPTIDE 1 nat polymer SRC HOMOLOGY 2 DOMAIN no no SIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFE TLQQLVQHYSERAAGLSSRLVVPSHK SIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFE TLQQLVQHYSERAAGLSSRLVVPSHK F polypeptide(L) no yes EPQ(PTR)EEIPIYL EPQYEEIPIYL P polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia Escherichia coli sample BL21 LYSS 9606 Homo sapiens CYTOPLASM LYSS 469008 Escherichia coli BL21(DE3) BL21 (DE3) PRK172 Polyomavirus sample 10626 Hamster polyomavirus database_2 pdbx_database_related pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_conn struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1998-01-14 1 1 2008-03-24 1 2 2011-07-13 1 3 2021-11-03 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_related.content_type _pdbx_database_related.details _pdbx_database_status.process_site _struct_conn.pdbx_leaving_atom_flag _struct_conn.ptnr1_auth_comp_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr1_label_atom_id _struct_conn.ptnr1_label_comp_id _struct_conn.ptnr1_label_seq_id _struct_conn.ptnr2_auth_comp_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_atom_id _struct_conn.ptnr2_label_comp_id _struct_conn.ptnr2_label_seq_id _struct_ref_seq_dif.details ensemble Y BNL 1997-07-10 REL REL LEAST VIOLATIONS 200 1 NOESY DQF-COSY TOCSY HSQC NOESY-HSQC TOCSY-HSQC CBCA(CO)NH HCCH-TOCSY XF-NOESY XF-TOCSY 6.0 293 K REFINEMENT DETAILS CAN BE FOUND IN THE JRNL CITATION ABOVE. DYNAMICAL SIMULATED ANNEALING BRUNGER refinement X-PLOR 3.1 structure solution X-PLOR 500 Home-built OMEGA 600 Home-built OMEGA 750 Home-built OMEGA SER 1 n 1 SER 1 F ILE 2 n 2 ILE 2 F GLN 3 n 3 GLN 3 F ALA 4 n 4 ALA 4 F GLU 5 n 5 GLU 5 F GLU 6 n 6 GLU 6 F TRP 7 n 7 TRP 7 F TYR 8 n 8 TYR 8 F PHE 9 n 9 PHE 9 F GLY 10 n 10 GLY 10 F LYS 11 n 11 LYS 11 F LEU 12 n 12 LEU 12 F GLY 13 n 13 GLY 13 F ARG 14 n 14 ARG 14 F LYS 15 n 15 LYS 15 F ASP 16 n 16 ASP 16 F ALA 17 n 17 ALA 17 F GLU 18 n 18 GLU 18 F ARG 19 n 19 ARG 19 F GLN 20 n 20 GLN 20 F LEU 21 n 21 LEU 21 F LEU 22 n 22 LEU 22 F SER 23 n 23 SER 23 F PHE 24 n 24 PHE 24 F GLY 25 n 25 GLY 25 F ASN 26 n 26 ASN 26 F PRO 27 n 27 PRO 27 F ARG 28 n 28 ARG 28 F GLY 29 n 29 GLY 29 F THR 30 n 30 THR 30 F PHE 31 n 31 PHE 31 F LEU 32 n 32 LEU 32 F ILE 33 n 33 ILE 33 F ARG 34 n 34 ARG 34 F GLU 35 n 35 GLU 35 F SER 36 n 36 SER 36 F GLU 37 n 37 GLU 37 F THR 38 n 38 THR 38 F THR 39 n 39 THR 39 F LYS 40 n 40 LYS 40 F GLY 41 n 41 GLY 41 F ALA 42 n 42 ALA 42 F TYR 43 n 43 TYR 43 F SER 44 n 44 SER 44 F LEU 45 n 45 LEU 45 F SER 46 n 46 SER 46 F ILE 47 n 47 ILE 47 F ARG 48 n 48 ARG 48 F ASP 49 n 49 ASP 49 F TRP 50 n 50 TRP 50 F ASP 51 n 51 ASP 51 F ASP 52 n 52 ASP 52 F MET 53 n 53 MET 53 F LYS 54 n 54 LYS 54 F GLY 55 n 55 GLY 55 F ASP 56 n 56 ASP 56 F HIS 57 n 57 HIS 57 F VAL 58 n 58 VAL 58 F LYS 59 n 59 LYS 59 F HIS 60 n 60 HIS 60 F TYR 61 n 61 TYR 61 F LYS 62 n 62 LYS 62 F ILE 63 n 63 ILE 63 F ARG 64 n 64 ARG 64 F LYS 65 n 65 LYS 65 F LEU 66 n 66 LEU 66 F ASP 67 n 67 ASP 67 F ASN 68 n 68 ASN 68 F GLY 69 n 69 GLY 69 F GLY 70 n 70 GLY 70 F TYR 71 n 71 TYR 71 F TYR 72 n 72 TYR 72 F ILE 73 n 73 ILE 73 F THR 74 n 74 THR 74 F THR 75 n 75 THR 75 F ARG 76 n 76 ARG 76 F ALA 77 n 77 ALA 77 F GLN 78 n 78 GLN 78 F PHE 79 n 79 PHE 79 F GLU 80 n 80 GLU 80 F THR 81 n 81 THR 81 F LEU 82 n 82 LEU 82 F GLN 83 n 83 GLN 83 F GLN 84 n 84 GLN 84 F LEU 85 n 85 LEU 85 F VAL 86 n 86 VAL 86 F GLN 87 n 87 GLN 87 F HIS 88 n 88 HIS 88 F TYR 89 n 89 TYR 89 F SER 90 n 90 SER 90 F GLU 91 n 91 GLU 91 F ARG 92 n 92 ARG 92 F ALA 93 n 93 ALA 93 F ALA 94 n 94 ALA 94 F GLY 95 n 95 GLY 95 F LEU 96 n 96 LEU 96 F SER 97 n 97 SER 97 F SER 98 n 98 SER 98 F ARG 99 n 99 ARG 99 F LEU 100 n 100 LEU 100 F VAL 101 n 101 VAL 101 F VAL 102 n 102 VAL 102 F PRO 103 n 103 PRO 103 F SER 104 n 104 SER 104 F HIS 105 n 105 HIS 105 F LYS 106 n 106 LYS 106 F GLU 201 n 1 GLU 201 P PRO 202 n 2 PRO 202 P GLN 203 n 3 GLN 203 P PTR 204 n 4 PTR 204 P GLU 205 n 5 GLU 205 P GLU 206 n 6 GLU 206 P ILE 207 n 7 ILE 207 P PRO 208 n 8 PRO 208 P ILE 209 n 9 ILE 209 P TYR 210 n 10 TYR 210 P LEU 211 n 11 LEU 211 P author_defined_assembly 2 dimeric P PTR 204 O-PHOSPHOTYROSINE B PTR 4 TYR 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 F O ILE 47 A O ILE 47 F N LYS 59 A N LYS 59 F O ARG 64 A O ARG 64 F N TYR 72 A N TYR 72 1 F ARG 19 0.087 SIDE CHAIN 1 F ARG 28 0.221 SIDE CHAIN 1 F ARG 34 0.145 SIDE CHAIN 1 F ARG 48 0.128 SIDE CHAIN 1 F ARG 76 0.307 SIDE CHAIN 1 F ARG 92 0.288 SIDE CHAIN 1 F ARG 99 0.202 SIDE CHAIN 1 F ILE 2 -54.56 -167.89 1 F ALA 4 44.55 26.97 1 F GLU 5 -179.53 41.13 1 F GLU 6 -162.31 -69.08 1 F LYS 11 -105.44 69.30 1 F PHE 24 57.68 110.71 1 F PRO 27 -78.14 -159.14 1 F ARG 34 177.58 158.71 1 F ASP 52 -85.10 44.22 1 F MET 53 -161.80 20.41 1 F LYS 54 -174.73 -29.63 1 F LYS 59 -104.22 -166.62 1 F ALA 94 93.19 -20.16 1 F LEU 100 -49.02 -175.23 1 F PRO 103 -78.03 -159.92 1 P PRO 208 -78.20 -169.97 1 P ILE 209 -175.48 31.16 model building X-PLOR 3.1 refinement X-PLOR 3.1 phasing X-PLOR 3.1 NMR STRUCTURE OF THE FYN SH2 DOMAIN COMPLEXED WITH A PHOSPHOTYROSYL PEPTIDE, MINIMIZED AVERAGE STRUCTURE 1 N N 2 N N F ARG 14 A ARG 14 HELX_P F LEU 22 A LEU 22 1 1 9 F LEU 82 A LEU 82 HELX_P F TYR 89 A TYR 89 1 2 8 covale 1.305 both P GLN 203 B C GLN 3 1_555 P PTR 204 B N PTR 4 1_555 covale 1.305 both P PTR 204 B C PTR 4 1_555 P GLU 205 B N GLU 5 1_555 COMPLEX (PROTO-ONCOGENE/EARLY PROTEIN) SH2 DOMAIN, SIGNAL TRANSDUCTION, PEPTIDE COMPLEX, COMPLEX (PROTO-ONCOGENE-EARLY PROTEIN), COMPLEX (PROTO-ONCOGENE-EARLY PROTEIN) complex FYN_HUMAN UNP 1 142 P06241 TAMI_POVHA UNP 2 321 P03079 142 247 1AOT 1 106 P06241 F 1 1 106 321 331 1AOT 201 211 P03079 P 2 1 11 1 CYS engineered mutation SER 97 1AOT F P06241 UNP 238 97 1 CYS engineered mutation SER 98 1AOT F P06241 UNP 239 98 1 CYS engineered mutation SER 104 1AOT F P06241 UNP 245 104 2 2 anti-parallel anti-parallel F SER 46 A SER 46 F ARG 48 A ARG 48 F VAL 58 A VAL 58 F HIS 60 A HIS 60 F ARG 64 A ARG 64 F LEU 66 A LEU 66 F GLY 70 A GLY 70 F TYR 72 A TYR 72 PHOSPHOTYROSINE BINDING SITE. Unknown 7 +3 ILE BINDING SITE. Unknown 5 F ARG 34 A ARG 34 7 1_555 F SER 36 A SER 36 7 1_555 F THR 38 A THR 38 7 1_555 F SER 44 A SER 44 7 1_555 F HIS 60 A HIS 60 7 1_555 F TYR 61 A TYR 61 7 1_555 F LYS 62 A LYS 62 7 1_555 F TYR 61 A TYR 61 5 1_555 F ILE 73 A ILE 73 5 1_555 F THR 74 A THR 74 5 1_555 F GLY 95 A GLY 95 5 1_555 F LEU 96 A LEU 96 5 1_555 1 P 1